Neuronetics STIM Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Gross Profit by Business | ||||||
| Medical Device | $45.62M-8.8% | $45.72M-13.6% | $58.69M+12.5% | $55.59M+8.7% | $50.01M-3.6% | |
| Operating Income by Business | ||||||
| Medical Device | $15.6M— | $14.12M— | —— | —— | —— | |
| Research And Development Expense by Business | ||||||
| Medical Device | $7.4M-45.3% | $7.66M-39.9% | $12.96M+187% | $13.36M+116% | $13.52M+70.4% | |
| Revenue by Product | ||||||
| Clinic Revenue | $89.85M+309% | $86.98M+1,857% | $64.6M— | $43.91M— | $21.99M— | |
| Neuro Star Advanced Therapy System | $15.77M+1.5% | $15.54M-3.5% | $14.79M-10.4% | $15.18M-5.1% | $15.54M-6.1% | |
| Treatment Sessions | $43.89M-8.7% | $44.41M-13.7% | $44.64M-16.4% | $47.3M-11.3% | $48.05M-11.0% | |
| Concentration Risk % by Product | ||||||
| Neuro Star Advanced Therapy System | 130%-1.0pp | 143%-7.0pp | 141%— | 151%— | 131%— | |
| Treatment Sessions | 224%— | 205%— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Neuronetics break its business down?
- Neuronetics (STIM) reports revenue by business across 2 parts — Clinical Services and Medical Device. Each is extracted from the segment footnotes and tracked over time.
- Where does Neuronetics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Neuronetics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
